Vaxxinity Inc Cl A (VAXX)

$0.00 0.00 (N/A)
Market Cap 51,000.00
Revenue (ttm) 0.00
Net Income (ttm) -56.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.99
Volume 600
Avg Vol 32,178
Day's Range N/A - N/A
Shares Out 126.75M
Stochastic %K 1%
Beta -17.72
Analysts Strong Buy
Price Target $7.00

Latest News on VAXX

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

Jun 20, 2024, 6:00 AM EDT - 7 months ago

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

Vaxxinity Issues Shareholder Letter

Apr 19, 2024, 6:53 PM EDT - 9 months ago

Vaxxinity Issues Shareholder Letter

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Apr 19, 2024, 4:27 PM EDT - 9 months ago

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Mar 28, 2024, 9:23 AM EDT - 10 months ago

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Mar 27, 2024, 4:41 PM EDT - 10 months ago

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

Mar 7, 2024, 10:32 AM EST - 11 months ago

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Feb 15, 2024, 8:00 AM EST - 1 year ago

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

Feb 13, 2024, 8:00 AM EST - 1 year ago

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

Jan 30, 2024, 8:00 AM EST - 1 year ago

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

Jan 18, 2024, 8:00 AM EST - 1 year ago

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 1 year ago

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

Nov 13, 2023, 6:50 PM EST - 1 year ago

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 8, 2023, 8:30 AM EST - 1 year ago

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity to Present at Upcoming Investor Conferences in September

Aug 29, 2023, 8:00 AM EDT - 1 year ago

Vaxxinity to Present at Upcoming Investor Conferences in September

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 9, 2023, 8:00 AM EDT - 1 year ago

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Jul 27, 2023, 4:30 PM EDT - 1 year ago

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 1 year ago

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Mar 28, 2023, 8:00 AM EDT - 1 year ago

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

Mar 27, 2023, 7:50 AM EDT - 1 year ago

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

Vaxxinity Joins TransCelerate Research and Development Consortium

Mar 21, 2023, 8:00 AM EDT - 1 year ago

Vaxxinity Joins TransCelerate Research and Development Consortium

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

Mar 20, 2023, 8:00 AM EDT - 1 year ago

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

Mar 2, 2023, 8:00 AM EST - 2 years ago

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena Podcast

Mar 1, 2023, 9:00 AM EST - 2 years ago

ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena Podcast

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

Feb 1, 2023, 7:40 PM EST - 2 years ago

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

Vaxxinity: Potential Strong Upsides Ahead

Jan 17, 2023, 7:58 AM EST - 2 years ago

Vaxxinity: Potential Strong Upsides Ahead

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Dec 2, 2022, 8:00 AM EST - 2 years ago

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 7:30 AM EST - 2 years ago

Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Vaxxinity to Present at Upcoming Investor Conferences in November

Nov 1, 2022, 9:00 AM EDT - 2 years ago

Vaxxinity to Present at Upcoming Investor Conferences in November

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Sep 13, 2022, 8:00 AM EDT - 2 years ago

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Aug 11, 2022, 8:00 AM EDT - 2 years ago

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines

Jul 25, 2022, 11:57 AM EDT - 2 years ago

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

May 9, 2022, 7:42 AM EDT - 2 years ago

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

Apr 6, 2022, 4:43 PM EDT - 3 years ago

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

Mar 24, 2022, 4:05 PM EDT - 3 years ago

Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

Mar 21, 2022, 7:00 AM EDT - 3 years ago

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

Vaxxinity's COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Feb 11, 2022, 9:28 AM EST - 3 years ago

Vaxxinity's COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity Announces First Parkinson's Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Jan 12, 2022, 9:21 AM EST - 3 years ago

Vaxxinity Announces First Parkinson's Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

Dec 23, 2021, 4:45 PM EST - 3 years ago

Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters' Option to Purchase Additional Shares

Nov 18, 2021, 4:05 PM EST - 3 years ago

Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters' Option to Purchase Additional Shares

Vaxxinity enjoys warm Wall Street reception as stock trades 20% above IPO price

Nov 11, 2021, 1:59 PM EST - 3 years ago

Vaxxinity enjoys warm Wall Street reception as stock trades 20% above IPO price

Vaxxinity Announces Pricing of Initial Public Offering

Nov 11, 2021, 6:30 AM EST - 3 years ago

Vaxxinity Announces Pricing of Initial Public Offering